Nino Dispensa

Dr. Nino Dispensa

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
CPCarlo Pavone
Carlo Pavone
FDFrancesco D’amato
Francesco D’amato
NDNino Dispensa
Nino Dispensa
FTFederico Torretta
Federico Torretta
CMCarlo Magno
Carlo Magno
Objective: To assess the proportion of patients with Peyronie’s Disease (PD) and the possible association with its potential risk factors in the general population of the central and western Sicily in our weekly andrological outpatient clinic. Materials and methods: We recruited a sample of 279 consecutive patients consulting our andrological outpatient clinic. Two arms were created: the first one composed by PD patients (men with symptoms suggestive for PD), the second one composed by patients with other andrological diseases (control arm). For each patient we evaluated the age, cigarette smoking, diabetes, blood hypertension and erectile function. In the PD arm we administered validated questionnaires to determine the erectile function status by the International Index of Erectile Function 5 (IIEF-5) and the pain status during erection by the Visual Analogue Scale (VAS). A univariate analysis was conducted using R software. Results: We enrolled 279 consecutive patients. The number of PD patients was 97 (34,7%). The univariate analysis showed a correlation between PD and cigarette smoking (p = 0.0242), blood hypertension (p < 0.001), erectile dysfunction (p < 0.001). No significant association was observed between diabetes and PD (p = 0.358). The median age of PD arm was 60 years and the median age of the control arm was 63,5 years; therefore the median age of PD arm resulted lower than the median age of the control arm (p = 0,031). Conclusions: Peyronie’s disease is more common than we might think; furthermore it can be diagnosed among young patients. According to our results, cigarette smoking and blood hypertension may be considered statically significant risk factors for developing PD. On the contrary diabetes seems not to be a risk factor for PD. According to our results PD should be sought also in young patients. Further studies are necessary to confirm that removing the indicated risk factors may reduce the incidence of PD.

1 September 2008 in Journal of Urology
Verified
Journal Article
Closed access
VSVincenzo Serretta
Vincenzo Serretta
ARAntonina Ruggirello
Antonina Ruggirello
NDNino Dispensa
Nino Dispensa
Rosalinda AllegroRosalinda Allegro
Rosalinda Allegro
FAFederico Aragona
Federico Aragona
DMDarvinio Melloni
Darvinio Melloni
Purpose: In the absence of Tis tumor we assessed whether history and multiplicity have a detrimental effect on conservative treatment in carefully selected patients with T1G3 bladder carcinoma.Mate...

26 September 2003 in BJU International
Verified
Journal Article
Closed access
PDF file
VSV. Serretta
V. Serretta
GDG. Daricello
G. Daricello
NDNino Dispensa
Nino Dispensa
Rosalinda AllegroRosalinda Allegro
Rosalinda Allegro
CPC. Pavone
C. Pavone
MPM. Pavone‐Macaluso
M. Pavone‐Macaluso

7 May 2026 in Radiation
Verified
Journal Article
Open access
PDF file
VOVilla Santa Teresa/UO Radioterapia Oncologica
Villa Santa Teresa/UO Radioterapia Oncologica
Albert ComelliAlbert Comelli
Albert Comelli
ADAndrea D'Aviero
Andrea D'Aviero
NDNino Dispensa
Nino Dispensa
NPNicola Pavan
Nicola Pavan
LBLuca Boldrini
Luca Boldrini
Introduction: Radiotherapy (RT) plays a crucial role in the management of prostate cancer (PC). Artificial intelligence (AI) is reshaping cancer care by providing innovative tools for diagnosis, treatment optimization, and outcome prediction. This review provides an end-to-end synthesis of AI applications across the prostate RT workflow, critically evaluating their clinical maturity, level of evidence, and current barriers to real-world implementation. Methods: A literature review of PubMed/MEDLINE and Embase was conducted to investigate the impact of AI on prostate RT. Only original articles published up to 1 August 2025 were included. The 27 selected studies were categorized into the following clusters: adaptive radiotherapy, autocontouring, autoplanning, prediction, synthetic computed tomography (CT), quality assurance (QA), and tracking. Results: Autocontouring was the most represented cluster, followed by prediction, autoplanning, and adaptive RT. Fewer studies addressed tracking, QA, and synthetic CT. Conclusions: AI shows significant potential across multiple phases of the prostate RT workflow; however, most evidence is based on retrospective or technical validation studies. Further research is required to establish clinical benefit and support integration into personalized treatment strategies.

1 April 2012 in Urologia Journal
Verified
Journal Article
Closed access
SRSalvatore Romeo
Salvatore Romeo
GNGiancarlo Napoli
Giancarlo Napoli
GMGuglielmo Melloni
Guglielmo Melloni
NDNino Dispensa
Nino Dispensa
DMDarwin Melloni
Darwin Melloni
The functional relationship between parathyroid glands and prostatic gland is commonly very well known. The aim of our study was to investigate the relationship between serum levels of PTH and serum levels of PSA in patients with pathological finding of BPH. According to 261 transrectal ultrasound-guided prostatic biopsies performed from March 2009 to March 2010, 75 patients, responding to our inclusion criteria, were selected. 26 patients (34.6%) ended the study. All patients with high serum levels of PSA (>4 ng/mL), with histological diagnosis of benign prostatic hyperplasia, underwent the assay of serum levels of PTH. We observed high levels of PTH (> 66 pg/mL) in 9 patients (35.2%).

26 September 2013 in Urologia Journal
Verified
Journal Article
Closed access
VSVincenzo Serretta
Vincenzo Serretta
SSSalvatore Scurria
Salvatore Scurria
NDNino Dispensa
Nino Dispensa
GCGaetano Chiapparrone
Gaetano Chiapparrone
SPSandro Provenzano
Sandro Provenzano
ARAntonio Russo
Antonio Russo
To reduce the number of negative prostate biopsies in patients with elevated PSA serum levels represents a major challenge in urological oncology. Angiogenetic factors might be involved in initial stages of prostate cancer and might represent useful tools in patients’ selection for prostate biopsy. The plasmatic levels of Angiopoietin-2, Follistatin, G-CSF, HGF, IL-8, Leptin, PDGF-BB, PECAM-1 and VEGF were measured by BioPlex immunoassay in patients undergoing prostate biopsy for palpable prostate nodule and/or elevated PSA levels (≥4 ng/mL). They were related with biopsy results. ROC curve analysis was exploited to test the diagnostic accuracy of each biomarker by AUC calculation. A potential cut-off level was computed. Fifty patients were entered. Median PSA was 6.8 ng/mL. A prostate nodule was palpable in 18 (36%) patients. The median number of biopsy cores was 12. Prostate cancer was detected in 25 (50%) and ASAP and PIN in 2 more patients (4%) respectively. Among the 9 considered biomarkers, only leptin showed an interesting diagnostic performance with an AUC of 0.781, at a cut-off value of 2.11 ng/mL, demonstrating a sensitivity of 78%, a specificity of 77% and a positive predictive value of 85%. Main limitations of our study are the exploratory design and the criteria adopted for patients’ selection determining a detection rate for prostate cancer above the usual range. Leptin only, in our preliminary study, shows promising diagnostic accuracy for the selection of patients candidate to prostate biopsy. Further studies are required to confirm its diagnostic value and its relation with BMI.